Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å vurdere uønskede hendelser, endring i sykdomsaktivitet og hvordan intravenøs og subkutan risankizumab beveger seg gjennom kroppen til pediatriske deltakere med moderat til alvorlig aktiv Crohns sykdom (RISE)

15. oktober 2026 oppdatert av: AbbVie

En fase 3, multisenterstudie for å evaluere farmakokinetikken, effektiviteten og sikkerheten til risankizumab med åpen induksjon, randomisert dobbeltblind vedlikehold og langsiktige forlengelsesperioder hos pediatriske personer (2 til <18 år) med Moderat til alvorlig aktiv Crohns sykdom

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.

Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.

Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Studieoversikt

Status

Rekruttering

Forhold

Studietype

Intervensjonell

Registrering (Antatt)

110

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Brussels, Belgia, 1020
        • Rekruttering
        • Hospital Universite Enfants Reine Fabiola /ID# 255112
      • Liège, Belgia, 4000
        • Rekruttering
        • Groupe Sante CHC - Clinique du MontLegia /ID# 255620
    • Antwerpen
      • Edegem, Antwerpen, Belgia, 2650
        • Rekruttering
        • Uza /Id# 255114
    • Brussels Capital
      • Brussels, Brussels Capital, Belgia, 1200
        • Rekruttering
        • Cliniques Universitaires UCL Saint-Luc /ID# 255108
      • Jette, Brussels Capital, Belgia, 1090
        • Rekruttering
        • Universitair Ziekenhuis Brussel /ID# 255109
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgia, 3000
        • Rekruttering
        • Universitair Ziekenhuis Leuven /ID# 255098
      • Plovdiv, Bulgaria, 4002
        • Rekruttering
        • UMHAT Sveti Georgi EAD /ID# 255386
      • Sofia, Bulgaria, 1606
        • Fullført
        • Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
      • Varna, Bulgaria, 9009
        • Rekruttering
        • UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Rekruttering
        • Alberta Children's Hospital /ID# 255357
      • Edmonton, Alberta, Canada, T6G 1C9
        • Rekruttering
        • Edmonton Clinic Health Academy /ID# 255361
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • Rekruttering
        • BC Children's Hospital /ID# 255359
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Rekruttering
        • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
    • Arizona
      • Phoenix, Arizona, Forente stater, 85016-7710
        • Rekruttering
        • Phoenix Children's Hospital /ID# 255766
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72202
        • Fullført
        • Arkansas Children's Hospital /ID# 255762
    • California
      • Oakland, California, Forente stater, 94609
        • Rekruttering
        • UCSF Benioff Children's Hospital - Oakland /ID# 258327
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Children's Hospital Colorado - Aurora /ID# 255764
    • Florida
      • Orlando, Florida, Forente stater, 32806-1141
        • Rekruttering
        • Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Indiana University Health Riley Hospital for Children /ID# 256454
    • Massachusetts
      • Waltham, Massachusetts, Forente stater, 02451
        • Rekruttering
        • Massachusetts General Hospital - Mass General Waltham /ID# 255767
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55413-2195
        • Rekruttering
        • MNGI Digestive Health, P. A. /ID# 255366
    • New Jersey
      • Morristown, New Jersey, Forente stater, 07960
        • Rekruttering
        • Goryeb Childrens Hospital /ID# 256452
    • New York
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai /ID# 254880
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Rekruttering
        • Cleveland Clinic - Cleveland /ID# 256453
        • Ta kontakt med:
          • Site Coordinator
          • Telefonnummer: 216-636-2007
      • Paris, Frankrike, 75015
        • Rekruttering
        • AP-HP - Hopital Necker /ID# 255608
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, Frankrike, 37044
        • Rekruttering
        • CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrike, 33076
        • Rekruttering
        • Chu Bordeaux - Hopital Pellegrin /ID# 257060
    • Occitanie
      • Toulouse, Occitanie, Frankrike, 31059
        • Rekruttering
        • CHU Toulouse - Hopital Paule de Viguier /ID# 255609
    • Rhone
      • Bron, Rhone, Frankrike, 69500
        • Rekruttering
        • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
    • Central District
      • Petah Tikva, Central District, Israel, 4920235
        • Rekruttering
        • Schneider Children's Medical Center /ID# 254950
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 91031
        • Rekruttering
        • Shaare Zedek Medical Center /ID# 254951
      • Messina, Italia, 98125
        • Rekruttering
        • Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
    • Genova
      • Genoa, Genova, Italia, 16147
        • Rekruttering
        • IRCCS Istituto Giannina Gaslini /ID# 255262
    • Napoli
      • Naples, Napoli, Italia, 80131
        • Rekruttering
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
    • Roma
      • Rome, Roma, Italia, 00165
        • Rekruttering
        • Ospedale Pediatrico Bambino Gesu /ID# 255043
    • Aichi-ken
      • Ōbu, Aichi-ken, Japan, 474-8710
        • Rekruttering
        • Aichi Children's Health And Medical Center /ID# 272085
    • Chiba
      • Kashiwa-shi, Chiba, Japan, 277-0871
        • Rekruttering
        • Tsujinaka Hospital - Kashiwanoha /ID# 268409
    • Fukuoka
      • Kurume-shi, Fukuoka, Japan, 830-0011
        • Rekruttering
        • Kurume University Hospital /ID# 268418
    • Gunma
      • Maebashi, Gunma, Japan, 371-8511
        • Rekruttering
        • Gunma University Hospital /ID# 270560
    • Kumamoto
      • Kumamoto, Kumamoto, Japan, 861-8520
        • Rekruttering
        • Japanese Red Cross Kumamoto Hospital /ID# 268586
    • Osaka
      • Izumi-Shi, Osaka, Japan, 594-1101
        • Rekruttering
        • Osaka Women's and Children's Hospital /ID# 268419
    • Saitama
      • Saitama-shi, Saitama, Japan, 330-8777
        • Rekruttering
        • Saitama Children's Medical Center /ID# 268410
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 113-8519
        • Rekruttering
        • Institute of Science Tokyo Hospital /ID# 269175
      • Fuchu-shi, Tokyo, Japan, 183-8561
        • Rekruttering
        • Tokyo Metropolitan Children's Medical Center /ID# 268415
      • Setagaya City, Tokyo, Japan, 157-8535
        • Rekruttering
        • National Center For Child Health And Development /ID# 268420
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100045
        • Rekruttering
        • Beijing Children's Hospital /ID# 256081
      • Beijing, Beijing Municipality, Kina, 100191
        • Rekruttering
        • Peking University Third Hospital /ID# 255876
        • Ta kontakt med:
          • Site Coordinator
          • Telefonnummer: +86 010-82266699
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510620
        • Rekruttering
        • Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
      • Guangzhou, Guangdong, Kina, 510655
        • Rekruttering
        • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
    • Henan
      • Zhengzhou, Henan, Kina, 450018
        • Rekruttering
        • Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
    • Hunan
      • Changsha, Hunan, Kina, 410007
        • Rekruttering
        • Hunan Children's Hospital /ID# 255610
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • Rekruttering
        • Jiangxi Provincial Children's Hospital /ID# 255564
    • Liaoning
      • Shenyang, Liaoning, Kina, 110022
        • Rekruttering
        • Shengjing Hospital of China Medical University /ID# 255563
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200062
        • Rekruttering
        • Children's Hospital of Shanghai /ID# 255531
      • Shanghai, Shanghai Municipality, Kina, 200065
        • Rekruttering
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
    • North Holland
      • Amsterdam, North Holland, Nederland, 1105 AZ
        • Rekruttering
        • Amsterdam University Medical Center /ID# 254827
    • Kuyavian-Pomeranian Voivodeship
      • Torun, Kuyavian-Pomeranian Voivodeship, Polen, 87-100
        • Fullført
        • Gastromed Sp. z o.o /ID# 255939
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 04-730
        • Rekruttering
        • Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
      • Dorado, Puerto Rico, 00646
        • Rekruttering
        • Puerto Rico Health Institute /ID# 255071
      • San Juan, Puerto Rico, 00909-1711
        • Rekruttering
        • Clinical Research Puerto Rico /ID# 266479
      • Madrid, Spania, 28009
        • Fullført
        • Hospital Infantil Universitario Nino Jesus /ID# 255012
      • Málaga, Spania, 29011
        • Rekruttering
        • Hospital Regional Universitario de Malaga /ID# 257553
    • A Coruna
      • Ferrol, A Coruna, Spania, 15405
        • Rekruttering
        • Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
      • Birmingham, Storbritannia, B4 6NH
        • Rekruttering
        • Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
    • England
      • Sheffield, England, Storbritannia, S10 2TH
        • Rekruttering
        • Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
        • Ta kontakt med:
          • Site Coordinator
          • Telefonnummer: +44 114 273 0522
    • Greater London
      • London, Greater London, Storbritannia, E1 2ES
        • Rekruttering
        • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
      • Bern, Sveits, 3010
        • Rekruttering
        • Inselspital, Universitaetsspital Bern /ID# 255321
    • Canton of Zurich
      • Zurich, Canton of Zurich, Sveits, 8032
        • Rekruttering
        • Kinderspital Zurich - Eleonorenstiftung /ID# 255337
    • Stockholm County
      • Stockholm, Stockholm County, Sverige, 118 83
        • Rekruttering
        • Sodersjukhuset /ID# 255239
      • Stockholm, Stockholm County, Sverige, 171 76
        • Rekruttering
        • Astrid Lindgrens Barnsjukhus /ID# 255240
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Sverige, 413 46
        • Rekruttering
        • Sahlgrenska Universitetssjukhuset /ID# 255236
        • Ta kontakt med:
          • Site Coordinator
          • Telefonnummer: +46313435865
      • Daegu, Sør -Korea, 41404
        • Rekruttering
        • Kyungpook National University Chilgok Hospital /ID# 255817
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Sør -Korea, 03080
        • Rekruttering
        • Seoul National University Hospital /ID# 255318
      • Seoul, Seoul Teugbyeolsi, Sør -Korea, 06351
        • Rekruttering
        • Samsung Medical Center /ID# 255284
      • Seoul, Seoul Teugbyeolsi, Sør -Korea, 03722
        • Rekruttering
        • Yonsei University Health System - Severance Hospital /ID# 256976
      • Changhua City, Changhua County, Taiwan, 50006
        • Rekruttering
        • Changhua Christian Hospital /ID# 256082
      • Taipei, Taiwan, 100
        • Rekruttering
        • National Taiwan University Hospital /ID# 255679
    • Praha 17
      • Prague, Praha 17, Tsjekkia, 128 00
        • Fullført
        • Vseobecna Fakultni nemocnice v Praze /ID# 256096
    • Praha 5
      • Prague, Praha 5, Tsjekkia, 150 06
        • Fullført
        • Fakultni nemocnice Motol a Homolka /ID# 256547
      • Ankara, Tyrkia (Türkiye), 06560
        • Rekruttering
        • Gazi University Medical Faculty /ID# 255086
      • Istanbul, Tyrkia (Türkiye), 34453
        • Rekruttering
        • Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
      • Istanbul, Tyrkia (Türkiye), 34899
        • Rekruttering
        • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
      • Kocaeli, Tyrkia (Türkiye), 41380
        • Rekruttering
        • Kocaeli University Med Faculty /ID# 256922
    • Bavaria
      • Munich, Bavaria, Tyskland, 80337
        • Rekruttering
        • Dr. von Haunerschen Kinderspital /ID# 255577
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Tyskland, 48149
        • Rekruttering
        • Universitaetsklinikum Muenster /ID# 256762

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 17 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Pediatric individuals, 2 to < 18 years old
  • Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
  • Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
  • Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies

Exclusion Criteria:

  • History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class

  • Any of the following medical disorders:

    1. Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.

    2. A diagnosis of CD prior to 2 years of age.

    3. A diagnosis or suspected diagnosis of a primary immunodeficiency.

    4. Currently known complications of CD such as:

      • Active abscess (abdominal or perianal);
      • Symptomatic bowel strictures;
      • > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
      • Fulminant colitis;
      • Toxic megacolon;
      • Or any other manifestation that might require surgery while enrolled in the study.
    5. Ostomy or ileoanal pouch.

    6. Diagnosis of short gut or short bowel syndrome.

    7. Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PK Cohort 1: SS3 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 1: SS3 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 2: SS1

Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 2: SS3 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 2: SS3 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: Expansion Cohort 3: SS3 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: Expansion Cohort 3: SS3 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 1: SS1

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 1: SS2 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 1: SS2 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 2: SS2 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: PK Cohort 2: SS2 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: Expansion Cohort 3: SS1

Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: Expansion Cohort 3: SS2 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI
Eksperimentell: Expansion Cohort 3: SS2 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Andre navn:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Andre navn:
  • ABBV-066
  • SKYRIZI

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Tidsramme: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Tidsramme: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Tidsramme: Up to approximately Week 64

Cmax of risankizumab

Up to approximately Week 64
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Tidsramme: Up to approximately 64 weeks

Tmax of risankizumab

Up to approximately 64 weeks
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Tidsramme: Up to approximately 64 weeks

AUCtau of risankizumab

Up to approximately 64 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Tidsramme: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tidsramme: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Tidsramme: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Tidsramme: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tidsramme: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Tidsramme: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Tidsramme: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Tidsramme: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Tidsramme: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: ABBVIE INC., AbbVie

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

11. desember 2023

Primær fullføring (Antatt)

1. april 2029

Studiet fullført (Antatt)

1. april 2029

Datoer for studieregistrering

Først innsendt

10. august 2023

Først innsendt som oppfylte QC-kriteriene

10. august 2023

Først lagt ut (Faktiske)

16. august 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • M16-194
  • 2022-502050-14-00 (Annen identifikator: EU CT)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Tilgangskriterier for IPD-deling

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere